-
Chengdu Kanghua Biological Products Inks Five-Year Partnership to Boost Sichuan’s Biotech and Vaccine Industries
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a five-year strategic partnership with Sichuan Biopharmaceutical Industry Group Pharmaceutical Industry Group Co., Ltd and Sichuan Development Leading Capital Management Co., Ltd. The collaboration aims to pool resources and leverage mutual strengths to…
-
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has reported its financial results for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a significant year-on-year (YOY) increase of 16.81%. The net profits attributable to shareholders have risen…
-
Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report
•
CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its financial performance for the first half of 2024, with revenues reaching RMB 741 million (USD 104 million), marking a 16.81% increase year-on-year. Net profits attributable to shareholders have also seen robust growth, climbing to RMB…
-
Chengdu Kanghua Strikes Licensing Deal with HilleVax for Recombinant Norovirus Vaccine
•
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has entered into a licensing agreement with HilleVax Inc. (NASDAQ: HLVX), granting the US firm exclusive rights to develop, manufacture, and commercialize Kanghua’s recombinant hexavalent norovirus vaccine on a worldwide basis, excluding the Greater China region…
